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Estimating the Number of 
Antiretroviral Treatment Facilities 
Based on the Wilson–Blower Method
Ntambwe Malangu
The implementation of the comprehensive plan for the 
care, management, and treatment of HIV and AIDS in South 
Africa [1] needs to be supported by all. It is encouraging 
to note that Wilson and Blower [2] used South Africa to 
develop a novel method to determine the optimal strategy for 
allocating antiretroviral treatment (ART) sites among health-
care facilities (HCFs) in KwaZulu–Natal. 
An equitable allocation of HCFs is necessary to ensure 
that each individual with HIV will have an equal chance of 
receiving antiretroviral drugs (ARVs). We have applied their 
method to determine the number of ART HCFs per district 
in KwaZulu–Natal.
We ﬁ rst set out to assemble basic details about the 
KwaZulu–Natal health districts, namely, population and 
number of hospitals and ﬁ xed and mobile clinics. Secondly, 
by using population data as reported in the KwaZulu–
Natal Department of Health 2004 annual report [3], and 
based on a 10% HIV prevalence, we determined the HIV 
population per district and also as a percentage of the total 
HIV population in the province. Finally, we calculated the 
number of ART HCFs, based on the premise that 54 ART 
HCFs will serve 100% of the HIV population in the province. 
By contrasting the estimated number of ART HCFs with the 
current ART HCFs, we calculated the number of ART HCFs 
that still need to be established.
The national target for access to HCFs is 10,000 habitants 
per one ﬁ xed primary health-care (PHC) facility [2]. A PHC 
facility could be a clinic, a community health center, or a 
hospital. At present, there is one ﬁ xed PHC facility for 17,215 
inhabitants in KwaZulu–Natal [3]. 
With regard to ART, the 54 HCFs proposed by Wilson 
and Blower translate to 18,076 people with HIV per facility 
(Table 1). This number is close to the actual ﬁ gure of 17,215 
inhabitants per facility in the province.
In terms of equity, it could be argued, for instance, that the 
two facilities in the eThekwini district cannot be expected to 
provide ARVs to the estimated 319,994 individuals with HIV. 
In comparison, the Umziyathi, Amajuba, Umkhanyakude, 
Uthungulu, and Ugu districts currently have the same 
number of ART HCFs as eThekwini, but serve smaller 
populations (Table 1). This reﬂ ects the fact that the choice 
of the current facilities was guided more by practical 
considerations, such as availability of staff and infrastructure, 
than by the principle of equity as suggested by the World 
Health Organization [4].
From our calculations, it seems that in order to achieve 
treatment equity for individuals with HIV in KwaZulu–Natal, 
more ARV HCFs should be established as follows: 15 in 
eThekwini, four each in Umgungundlovu and Zululand, 
three each in Uthukela and Uthungulu, two each in Ugu and 
iLembe, and one each in Amajuba, Sisonke, Umzinyathi, and 
Umkhanyakude.
As a recommendation, future rollout of ART should take 
into consideration the principle of equity. This will ensure 
that all people with HIV have equal access to ARVs from their 
nearest HCF. We show that by applying the Wilson–Blower 
method, it is possible to determine the number of health-care 
facilities where ARVs would be equitably provided. 
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Table 1. Number of ART HCF Calculated for Each District
District Population HIV Population 
(Assuming 10% 
HIV Prevalence)
Percent of National 
HIV Population in 
District
Calculated 
Number of ARV  
HCFs Needed
Number of Current 
ARV HCFs
Number of 
Further ART HCFs 
Needed
DC-21-Ugu 729,052 72,905 7.5% 4 2 2
DC-22-Umgungundlovu 960,819 96,082 9.8% 5 1 4
DC-23-Uthukela 680,333 68,033 7% 4 1 3
DC-24-Umzinyathi 472,682 47,268 4.8% 3 2 1
DC-25-Amajuba 484,673 48,467 5% 3 2 1
DC-26-Zululand 833,037 83,304 8.5% 5 1 4
DC-27-Umkhanyakude 593,718 59,372 6.1% 3 2 1
DC-28-Uthungulu 917,451 91,745 9.4% 5 2 3
DC-29-iLembe 580,307 58,031 5.9% 3 1 2
DC-43-Sisonke 308,999 30,900 3.2% 2 1 1
Durban-eThekwini 3,199,944 319,994 32.8% 17 2 15
Total 9,761,015 976,102 100% 54 17 37
Source: Kwazulu–Natal Department of Health [2]. 
DOI: 10.1371/journal.pmed.0020270.t001
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Evidence-Based Medicine in 
Iberoamerica: Problems and Possible 
Solutions
Zulma Ortiz, Pablo Perel, Jordi Pardo
We want to congratulate Chinnock and colleagues, who 
summarize very well the main problems that evidence-based 
medicine faces in developing countries [1]. As members of 
the Iberoamerican Cochrane Network, we would like to share 
some lessons learned and highlight possible solutions to the 
problems identiﬁ ed by Chinnock et al. [1].
We have learned from the experience of working in and 
with Latin American countries that one of the ﬁ rst barriers 
to overcome is inequity in accessing evidence. The second 
barrier is the English language. Efforts have been made by 
our network to overcome both barriers by providing free 
access to Biblioteca Cochrane Plus (BCP) (http:⁄⁄www.
bibliotecacochrane.net ). In addition to systematic reviews 
and protocols, this database contains evidence-based 
information not indexed in other sources. 
However, ensuring access does not necessarily mean that 
reviews will be used in decision making. Many local problems 
do not appear in the BCP material, but those that are most 
prevalent and those with high impact on public health and 
clinical practice of these countries have been reviewed. 
Nevertheless, few health professionals apply the results of 
such reviews. One possible solution is that Cochrane centers, 
groups, or ﬁ elds, most of which are based in developed 
countries, could invest resources in mass dissemination and 
promote their activities through organizations such as the 
Pan American Health Organization. This would encourage 
not only the use of systematic reviews, but also promote 
an interest in the Cochrane Collaboration from health 
authorities in the Americas. 
Another aspect revealed in Chinnock et al.’s article is the 
need to get more people from developing countries involved 
in writing and peer-reviewing systematic reviews. The nature 
of the Cochrane Collaboration facilitates this, and we have 
had excellent results when working with several of its groups 
and ﬁ elds. However, developing countries have a limited 
number of people qualiﬁ ed to participate in the writing and 
peer-reviewing of systematic reviews. Most of those who have 
the necessary skills also have an enormous load of teaching 
and clinical care, their salaries are insufﬁ cient to support a 
white-collar lifestyle, and, thus, private practice is the most 
common means of augmenting earnings. These economic 
issues are by far the major factor underlying the relative lack 
of research in developing countries [2]. Cochrane groups 
and centers based in developed countries should identify 
potential reviewers in developing countries and invest 
resources that provide them with spare time to devote to the 
promotion, production, and evaluation of systematic reviews. 
This idea is in line with the Millennium Development Goals 
[3], speciﬁ cally number eight, which addresses the need to 
develop a global partnership for development. Nevertheless, 
the concerns exposed by Chinnock and colleagues in 
connection with the search for reviews performed in 
developing countries would decrease if the use of databases 
speciﬁ c to these regions, such as LILACS (Literatura 
Latinoamericana en Ciencias de la Salud) in Latin America, 
was encouraged and if the use and development of these 
databases were supported.
Finally, we consider that advocacy on the importance 
of research and evidence-based public health should be 
strengthened in developing countries. This has been 
highlighted by Bernardo Houssay, the ﬁ rst Latin American 
honored with the Nobel Prize, who said, “Science is only 
science when it involves constant progress and improvement 
arising from research. Thus, there are only two possible 
standpoints: that of tuggers and that of others being tugged. 
In other words, you may either create knowledge at the same 
time others do, or accept a subordinate position and depend 
on what others produce.” When the response to his views was 
different from what he expected, he added, “It would not be 
ethical to base a research strategy on the unfair exploitation 
of sacriﬁ ces made by those with exceptional and determined 
minds. Wise countries do not live waiting for saints or 
miracles to occur” (quoted in [4]). 
Zulma Ortiz (cie@epidemiologia.anm.edu.ar)
Pablo Perel 
Jordi Pardo
Argentine Collaborating Center of the Iberoamerican Cochrane Network
Buenos Aires, Argentina
References
1. Chinnock P, Siegfried N, Clarke M (2005) Is evidence-based medicine 
relevant to the developing world? PLoS Med 2: e107. DOI: 10.1371/journal.
pmed.0020107
2. Bhutta Z (2003) Practising just medicine in an unjust world. BMJ 327: 
1000–1001.
3. United Nations (2000) UN Millennium development goals. New York: 
United Nations. Available: http:⁄⁄www.un.org/millenniumgoals⁄. Accessed 
18 July 2005. 
4. Charreau EH (2004 May 13) Incorporación a la Academia Nacional de 
Medicina. Buenos Aires: Consejo Nacional de Investigaciones Cientíﬁ cas y 
Técnicas. Available: http:⁄⁄www.conicet.gov.ar/NOTICIAS/2004/Abril/
nota06.php. Accessed 21 July 2005.
Citation: Ortiz Z, Perel P, Pardo J (2005) Evidence-based medicine in Iberoamerica: 
problems and possible solutions. PLoS Med 2(8): e277.
Copyright: © 2005 Ortiz et al. This is an open-access article distributed under the 
terms of the Creative Commons Attribution License, which permits unrestricted 
use, distribution, and reproduction in any medium, provided the original work is 
properly cited.
Competing Interests: The authors have declared that no competing interests exist.
DOI: 10.1371/journal.pmed.0020277
PLoS Takes a Step Backward
John J. Pippin
The only people who don’t know in 2005 that animal 
research is irrelevant for human disease are those who 
don’t understand it or those who beneﬁ t from it. As a 
physician, clinical researcher, and former animal researcher, 
I know that though they are our closest genetic relatives, 
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primates have failed as research models virtually whenever 
they have been used. 
As a partial list of failures, allow me to submit the notorious 
forced smoking experiments, which allowed cigarettes to be 
promoted widely for decades; the abject failure of a quarter-
century of primate research on AIDS to provide any useful 
insights; the false leads and dangerous vaccines produced 
during polio research (veriﬁ ed by Albert Sabin, himself); the 
failure of primate studies to improve risks for birth defects 
and premature births; and the failure of monkey studies to 
identify nonsteroidal anti-inﬂ ammatory drug cardiovascular 
risk [1]. 
The PLoS Medicine editors state in hopeful language that 
the Lassa fever vaccine was successful in four monkeys, and, 
thus, is a suitable agent for human study [2]. Recall that 
VaxGen’s AIDS vaccine (AIDSVAX) showed great success 
in primate studies, but was an abject failure in two human 
clinical trials, including a trial of over 2,500 injection drug 
users in Thailand [3] and a multinational trial of over 5,000 
high-risk individuals [4].
Consider the fruitless decades-long effort to produce an 
AIDS vaccine in primates, the failure to produce even a 
single case of human AIDS in any primate studied, or the 
failure to identify even one useful AIDS drug from primate 
studies. Genetic and physiological imperatives dictate that 
no animal model, even higher primates, gives information 
applicable to humans. The Human Genome Project [5] tells 
us that there is sufﬁ cient genetic diversity among humans 
that pharmacogenetic and pharmacogenomic techniques 
will have an increasing role in overcoming problems related 
to polymorphisms and other variations. We can’t even apply 
scientiﬁ c ﬁ ndings uniformly to humans, and PLoS Medicine is 
now promoting monkey research? 
I am very disappointed that PLoS Medicine has regressed to 
reporting animal research. It is discouraging that in this era 
of rapid biomedical advancement, and appropriate relegation 
of animal research to the historical dustbin, PLoS has chosen 
to re-introduce an anachronistic, medically discredited, and 
unethical research tool to its reporting. 
John J. Pippin
Dallas, Texas, United States of America
E-mail: jjpippin@sbcglobal.net
References
1. Merck Research Laboratories (2000) Electrical injury model of arterial and 
venous thrombus formation in the anesthetized African green monkey: 
Measurement of prothrombotic and antithrombotic effects.
2. Barbour V, Cohen B, Yamey G (2005) Some tolerance for fur—Animal 
studies in PLoS Medicine. PLoS Med 2: e203. DOI: 10.1371/journal.
pmed.0020203
3. McCarthy M (2003) AIDS vaccine fails in Thai trial. Lancet 362: 1728.
4. McCarthy M (2003) HIV vaccine fails in phase 3 trial. Lancet 361: 755–756.
5. Human Genome Project Information (2005) Pharmacogenomics. 
Washington (DC): US Department of Energy Ofﬁ ce of Science. Available: 
http:⁄⁄www.ornl.gov/sci/techresources/Human_Genome/medicine/
pharma.shtml. Accessed 21 July 2005.
Citation: Pippin JJ (2005) PLoS takes a step backward. PLoS Med 2(8): e278.
Copyright: © 2005 John J. Pippin. This is an open-access article distributed under 
the terms of the Creative Commons Attribution License, which permits unrestricted 
use, distribution, and reproduction in any medium, provided the original work is 
properly cited.
Competing Interests: The author is a medical research consultant for the 
Physicians Committee for Responsible Medicine.
DOI: 10.1371/journal.pmed.0020278
Nanotechnology for the Poor?
Guillermo Foladori, Noela Invernizzi
After interviewing 63 experts, Salamanca-Buentello et al. 
[1] identiﬁ ed the ten main nanotechnologies that could 
provide a solution to problems involving water, agriculture, 
and health. Overﬂ owing with good intentions, the proposal 
reﬂ ects the idea that if a problem can be identiﬁ ed, all that 
has to be done is apply a suitable technology and it will be 
solved. Most of the examples do not take into account that 
the relationship between science and society is much more 
complex.
The authors suggest that quantum dots could detect HIV 
molecules in the early stages, facilitating the treatment and 
reducing the number of new cases. The authors seem to 
forget the story of recent years, which has been one of open 
war between multinational pharmaceutical corporations 
and countries seeking to manufacture antiretrovirals. 
Nanotechnology products are already being patented. A 
patent in the US costs US$30 000 in legal bureaucracy, and 
a worldwide patent may be as much as US$250 000 [2]. The 
moral of the story: the efﬁ ciency and implications of the 
application of technology depend on the social context.
The article identiﬁ es nanotechnology as the solution to ﬁ ve 
of the eight UN Millennium Development Goals [3]. Among 
these solutions are nanosensors to improve the dosage of 
water and fertilization of plants, and hopefully reduce poverty 
and hunger. Not so long ago, genetically modiﬁ ed organisms 
were hailed as the solution that would put an end to hunger. 
However, they ended up being used mainly in developed 
countries. There has been no improvement for developing 
countries; quite the contrary, transgenics turned up where 
they were not wanted, as was the case in Oaxaca [4]. The 
moral of the story: the choice of technology is not a neutral 
process. It is not necessarily true that the technology that is 
best and meets our needs will be the one to survive.
In a previous article [5] three of the same authors 
maintained that the position adopted by Prince Charles—
arguing that nanotechnology will widen the gap between rich 
and poor countries—and the position of the Action Group 
on Erosion, Technology and Concentration—requesting 
a moratorium on manufacture and commercialization of 
synthetic nanoparticles—both ignore the voices of people 
in developing countries. With their research the authors 
intended to ﬁ ll this gap. But the opinion of scientists involved 
in nanotechnology does not necessarily fall in with the 
most appropriate pathways for satisfying the needs of the 
poor. We may concur that infectious diseases are one of 
the main problems that the developing world is facing, but 
we may differ radically on how a solution to this problem 
should be attained. Prevention is not the same thing as cure. 
Nanotechnology is not necessary to reduce malaria radically, 
as is suggested by the authors. In Henan Province, China, 
malaria was reduced by 99% between 1965 and 1990 as a 
result of social mobilization, backed up by fumigation, the 
use of mosquito nets, and traditional medicine based on 
artemisinin [6]. Viet Nam reduced the number of malaria-
related deaths by 97% between 1992 and 1997 with similar 
methods [7]. The moral of the story: there are many means to 
an end, and technology is not always the solution. Organizing 
people can be just as important. 
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Why We Whistleblowers Are Passionate 
in Our Convictions
Stefan P. Kruszewski
Whistleblowers serve no function if they cannot tell their 
stories. The present story of whistleblowing—as discussed, 
in part, in PLoS Medicine—that involves the pharmaceutical 
industry, pharmaceutical beneﬁ t management corporations, 
the managed care industry, and the political and lobbying 
forces that zealously guard their secrets could not have been 
told without the help of courageous men and women [1, 2] 
For that reason, those of us who congregated in Washington, 
D.C., on May 15th, 2005, at the invitation and support of the 
Public Library of Science and the Government Accountability 
Project feel particularly humbled and grateful to these two 
sponsors. Our convictions could not have been aired were it 
not for the essential First Amendment work of responsible 
journalists, who exemplify the best in investigatory research.
For me, whistleblowing is not a theoretical exercise. It has 
a human face and tangible features. It is the face of children 
and adults who have been injured or killed by misrepresented 
pharmaceuticals; clinical research trial results that have 
been sequestered from the scientiﬁ c community and whose 
incomplete ﬁ ndings cause injury; and pharmaceuticals that 
are detailed to physicians, not to save lives or necessarily 
improve the health or welfare of the recipients, but to make 
money.
In the lonely and, at times, discouraging world of 
whistleblowing, we whistleblowers are passionate, and often 
successful, because our efforts have a different goal than 
the corporations and political interests whose operations 
we occasionally challenge. Our goal is to tell the truth. 
That honest effort is the source of any ethical difference 
we can or might make. Truth is the basis for the power 
of a whistleblower, one that can withstand the assault of 
unprecedented odds against being heard put forth by that 
sum of political power, expediency, and money. 
A whistleblower’s success depends upon competent and 
articulate media. The debate to improve the status quo—be 
it in pharmaceutical marketing or managed-care decision 
making—cannot proceed or ﬂ ourish without it. 
Ralph Waldo Emerson, American essayist and philosopher 
(1803–1882), commented about success (I have adapted his 
comments for all of us who gathered in Washington in mid-
May 2005): “To leave the world a bit better, whether by a 
healthy child, a garden patch or a redeemed social condition; 
to know even one life breathed easier because you have lived; 
this is to have succeeded [as a whistleblower].” 
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Future Scenarios for Academic 
Medicine Should Include Other 
Health Disciplines
Patrick McGrath
With reference to Awasthi and colleagues’ Policy Forum [1], 
International Campaign to Revitalise Academic Medicine 
(ICRAM) has done an excellent service by provoking 
thought about the future of academic medicine by outlining 
ﬁ ve scenarios. However, all of the scenarios are seriously 
deﬁ cient because they do not sufﬁ ciently incorporate 
in their vision other health disciplines and professions. 
Increasingly, translational research and knowledge transfer 
depend on interdisciplinary teams. Good patient care 
requires team approaches. Academic medicine is realizing 
the value of collaboration and is opening itself to disciplines 
such as nursing, psychology, occupational therapy, and 
physiotherapy. In addition, disciplines such as health 
informatics are vital. Envisioning the successful future of 
academic medicine requires collegial inclusion of other 
health-related disciplines. 
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August 2005  |  Volume 2  |  Issue 8  |  e280  |  e281  |  e282
PLoS Medicine  |  www.plosmedicine.org 0812
Halifax, Nova Scotia, Canada
E-mail: Patrick.McGrath@dal.ca
References
1. Awasthi S, Beardmore J, Clark J, Hadridge P, Madani H, et al. (2005) Five 
futures for academic medicine. PLoS Med 2: e207. DOI: 10.1371/journal.
pmed.0020207
Citation: McGrath P (2005) Future scenarios for academic medicine should include 
other health disciplines. PLoS Med 2(8): e282.
Copyright: © 2005 Patrick McGrath. This is an open-access article distributed under 
the terms of the Creative Commons Attribution License, which permits unrestricted 
use, distribution, and reproduction in any medium, provided the original work is 
properly cited.
Competing Interests: The author has declared that no competing interests exist.
DOI: 10.1371/journal.pmed.0020282
The Need for a New Specialist 
Professional Research System of “Pure” 
Medical Science
Bruce G. Charlton, Peter Andras
Awasthi et al.’s discussion of the future of academic medicine 
[1] is stimulating, but the primary focus of policy should be 
enhancing scientiﬁ c progress in medicine. Science policy 
should address the decline in major, clinically relevant 
“breakthroughs” over recent decades [2]. 
Medical research has become mostly an “applied” 
science, which implicitly aims at steady progress by an 
accumulation of small improvements, each increment 
having a high probability of validity. Applied medical 
science is therefore a social system of communications for 
generating pre-publication peer-reviewed knowledge ready 
for implementation [3]. However, the need for predictability 
dictated by peer reviewing of research funding and the need 
for a high probability of validity in published research makes 
modern medical science risk-averse. This has led to a decline 
in major therapeutic breakthroughs where new treatments for 
new diseases are required [2]. 
There is a need for the evolution of a specialized 
professional research system of pure medical science, where 
the major evaluation of validity occurs (in the manner of 
classic sciences) post-publication and by peer usage, rather 
than peer review [3,4]. The role of pure medical science 
would be to generate and critically evaluate radically novel 
and potentially important theories, techniques, therapies, and 
technologies.
Pure science ideas typically have a lower probability of 
being valid, but have the possibility of much greater beneﬁ t 
if they turn out to be true [5]. The domination of medical 
research by “applied” criteria means that even good ideas 
from pure medical science are typically ignored or rejected 
as being too speculative. It is possible to publish radical 
and potentially important ideas in medical science, but at 
present there is no formal mechanism by which pure science 
publications may be received, critiqued, evaluated, and 
extended to become suitable for “application”. 
Pure medical science needs to evolve to constitute a typical 
specialized scientiﬁ c system of formal communications 
among a professional community with close research 
groupings, journals, meetings, and electronic and Web 
communications—like any other science. However, the 
pure medical science system would have its own separate 
aims, procedures for scientiﬁ c evaluation, institutional 
organization, funding, and support arrangements, and it 
would have a separate higher professional career path with 
distinctive selection criteria. For instance, successful leaders 
of pure medical science institutions would need different 
qualities from many of the current leaders of medical 
science, and would need to be selected on the basis of their 
specialized cognitive aptitudes and their record of having 
generated science-transforming ideas.
The main “market” for pure medical science would be 
“applied” medical scientists who need radical strategies 
to solve important clinical problems that are not yielding 
to established methods. Pure medical science units might 
then arise as an elite grouping linked to existing world-class 
applied medical research institutions. The direct ﬁ nancial 
stimulus to create elite pure medical science institutions 
might come from the leadership of academic “entrepreneurs” 
and imaginative patrons in the major funding foundations. 
Bruce G. Charlton (bruce.charlton@ncl.ac.uk)
Peter Andras
University of Newcastle upon Tyne
Newcastle upon Tyne, United Kingdom
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